

KERN FAMILY HEALTH CARE MEETING OF THE PHARMACY AND THERAPEUTICS COMMITTEE AGENDA

DATE: August 30, 2006
TIME: 6:00 P.M.
PLACE: Hodel's Restaurant,
5917 Knudsen Drive (Hwy 99 and Olive Drive)
Bakersfield, Ca. 93308

The Agenda is divided into three sections:

CORRESPONDENCE AND CONSENT CALENDAR: These matters include routine non-policy financial and administrative actions, may include correspondence, and are usually approved by a single majority vote. Any Committee Member may remove an item from the correspondence and consent calendar.

REGULAR CALENDAR: These items include significant financial, administrative and policy matters.

CLOSED SESSION: These items include contracting, peer review, personnel and litigation matters and other issues to be discussed by Committee members only, with report to the public on any action taken.

REGULAR AGENDA CORRESPONDENCE AND CONSENT CALENDAR

1. Approval of the Minutes of April 26, 2006 meeting.
2. Approval of the following additions/changes to the formulary:
 - a. Allow all promethazine products to be restricted in members less than 2 yrs.
 - b. ACE/ARB protocol dependent on physician specialty.
 - c. True Track test strips: follow-up with Dr. Ettinger completed. Consult addition with PBM.
 - d. Ibuprofen—allow for members older than 6 months

REGULAR CALENDAR

I. PUBLIC COMMENT

This portion of the meeting is reserved for persons to address the Committee on any matter not on this agenda but under the jurisdiction of the Committee. They may ask a question for clarification, make a referral to staff for factual information or request staff to report back to the Committee at a later meeting.

Also, the Committee may take action to direct the staff to place a matter of business on a future agenda.

**SPEAKERS ARE LIMITED TO TWO MINUTES. PLEASE
STATE YOUR NAME BEFORE MAKING YOUR
PRESENTATION. THANK YOU!**

II. Action Items

Discussion and Possible Action Regarding Formulary Changes to the following:

A. DUR:

1. General – trends, drug groups, drugs
 - a. cost
 - b. volume
2. Generics First
3. Tablet splitting
4. IEHP collaboration
5. Qty limits
6. Generic potentials
7. albuterol mdi

B. Anti-Infective Therapy guidelines

C. Coreg-- guidelines

D. Diabetes

1. insulins/analog
2. guidelines

E. “Statin” review

F. Hepatitis C review

III. Adjourn

IV. Closed Session

1. Closed Session Regarding Peer Review
(California and Welfare Institutions Code
Section (14087.38(n))
 - a. Closed Session to discuss and discharge its
responsibility to evaluate and improve the
quality of care rendered by health facilities and
Health practitioners.
2. Closed Session Regarding Provider Rates and Contracts
(California Welfare and Institutions Code Section 14087.38(m))
 - a. Closed session to consider and take action of matters
pertaining to contracts, and contract negotiations with
providers of health care services concerning all matters
related to rate of payment.)

Next Regular meeting is scheduled for November 2006.

PLEASE NOTE: Anyone wishing information on the Kern Health Systems Pharmacy & Therapeutics Committee Agendas should contact Bruce Wearda, R.Ph., Corporate Pharmacist, at Kern Health Systems either by telephone at (661)664-5100 or in writing at the following address:

Kern Health Systems
9700 Stockdale Hwy
Bakersfield, CA 93311

Such requests must be received no later than 5:00 p.m. ten (10) calendared days prior to the next regularly scheduled Committee Meeting.